platinum has been researched along with olaparib in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 14 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnett, JC; Havrilesky, LJ; Ledermann, JA; Myers, ER; Peterson, BL; Secord, AA | 1 |
| Hutchinson, L | 1 |
| Bouberhan, S; Cannistra, SA; Shea, M | 1 |
| du Bois, A; Fielding, A; Friedlander, M; Gourley, C; Ledermann, J; Lowe, ES; Mann, H; Matei, D; Matulonis, U; McMurtry, EL; Meier, W; Parry, D; Rowe, P; Rustin, G; Safra, T; Scott, C; Selle, F; Shapira-Frommer, R; Shirinkin, V; Spencer, S; Vergote, I | 1 |
| Wu, L; Zhong, L | 1 |
| Gonzalez-Martin, A; Lorusso, D; Pignata, S | 1 |
| Blakeley, C; Davidson, R; Milner, A; Poveda, AM | 1 |
| Goto, M; Hori, K; Ito, K; Onoue, M; Takaki, E; Takei, T; Tashima, L; Tsuji, S; Yamashita, M; Yoshioka, E | 1 |
| Chan, JJ; Ghosh, W; Hettle, R; Tan, DS; Viswambaram, A; Yu, CC | 1 |
| Batter, S; Frank, RC; Kaplan, F; Kazanjian, M; Levy, G; Martignetti, J; Martino, C; Pandya, D; Shah, M | 1 |
| Choi, MC; Hwangbo, S; Kim, K; Kim, MK; Kim, SI; Kwak, YH; Lee, JM; Lee, JW; Lee, M; Shim, SH; Shin, SJ; Yoo, J | 1 |
| Barnicle, A; Bennett, J; Bjurberg, M; Blakeley, C; Cibula, D; Colombo, N; Davidson, R; González-Martín, A; Ledermann, J; Lheureux, S; Lindemann, K; Madry, R; Oaknin, A; Pérez, MJR; Poveda, A; Sikorska, M; Škof, E; Weberpals, J | 1 |
| Jimi, T; Kitai, M; Nagao, S; Nakazawa, H; Narita, M; Shibutani, T; Shiozaki, T; Yamaguchi, S; Yano, H | 1 |
| Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
| Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M | 1 |
| Bajorin, DF; Castellano, D; Dao, TV; Dry, H; Howells, K; Kozlov, V; Lanasa, MC; Li, JR; Mukherjee, SD; Park, SH; Rosenberg, JE; Stewart, R | 1 |
| Aoki, D; Chiyoda, T; Kobayashi, Y; Kuroda, Y; Nanki, Y; Sakai, K; Saotome, K; Takahashi, M; Yamagami, W; Yoshihama, T; Yoshimura, T | 1 |
| Kristeleit, RS; Moore, KN | 1 |
| Chen, SC; Lai, YH; Tung, KC | 1 |
| Hirai, T; Iwamoto, T; Ogura, T; Shiraishi, C | 1 |
| Furukawa, T; Hashimoto, H; Kawasaki, T; Kawazoe, H; Mamishin, K; Nakamura, T; Nishimura, T; Saito, Y; Seto, K; Shimoi, T; Tashiro, R; Terakado, H; Udagawa, R; Yonemori, K; Yonemura, M | 1 |
5 trial(s) available for platinum and olaparib
| Article | Year |
|---|---|
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Capsules; Cystadenocarcinoma, Serous; Disease-Free Survival; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Treatment Outcome; Young Adult | 2018 |
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2019 |
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum | 2022 |
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Phthalazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Urinary Bladder Neoplasms | 2023 |
Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases.
Topics: Anemia; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Piperazines; Platinum; United States | 2023 |
16 other study(ies) available for platinum and olaparib
| Article | Year |
|---|---|
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate | 2013 |
Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Tablets | 2017 |
Maintenance PARP inhibitor therapy: is maintaining quality of life enough?
Topics: Female; Humans; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States | 2019 |
Chemotherapy-free treatments: are we ready for prime time?
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time | 2019 |
[Efficacy of Olaparib Treatment for Platinum-Sensitive Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers].
Topics: Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum | 2020 |
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
Topics: Cost-Benefit Analysis; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Singapore | 2021 |
Treatment-emergent neuroendocrine prostate cancer with a germline
Topics: Aged; Androstenes; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Drug Resistance, Neoplasm; Drug Therapy; Genes, BRCA1; Genes, BRCA2; Germ Cells; Humans; Male; Mutation; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2021 |
Comparisons of survival outcomes between bevacizumab and olaparib in
Topics: Bevacizumab; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Republic of Korea | 2021 |
Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies | 2022 |
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.
Topics: Adenosine Diphosphate Ribose; Adult; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cisplatin; Fanconi Anemia Complementation Group A Protein; Female; Humans; Liver Neoplasms; Male; Mutation; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study.
Topics: BRCA1 Protein; BRCA2 Protein; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Retrospective Studies | 2023 |